| Document |
Document Title |
|
WO/2023/285981A1 |
The present invention relates to the pharmaceutical composition of Nilotinib or its pharmaceutically acceptable salts and process for preparation thereof. More particularly, the present invention relates to the liquid dosage form of Nilo...
|
|
WO/2023/285175A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2023/283372A1 |
This disclosure relates to compounds of Formula (A): Formula (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently att...
|
|
WO/2023/280970A1 |
The present invention relates to novel inhibitors of α-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections.
|
|
WO/2023/282414A1 |
The present invention relates to a novel compound exhibiting anti-inflammatory activity, and the compound of the present invention plays a critical role in the generation of pro-inflammatory cytokines, thereby having excellent inhibitory...
|
|
WO/2023/283130A1 |
The disclosure includes compounds of Formula (1), wherein each of RA, RB, R1, R2, R3, R4, Warhead, Z, Q4, W1, W2, m, n, i, and j, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and i...
|
|
WO/2023/283256A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/283338A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
|
WO/2023/283430A1 |
Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2). The compou...
|
|
WO/2023/282702A1 |
Provided are an inhibitor of SHP2, a pharmaceutical composition for preventing or treating diseases related to SHP2 comprising same, a method for treating and preventing diseases using same, and a use thereof. According to the present in...
|
|
WO/2023/283428A1 |
Disclosed are compounds l-A and I -B and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2).
|
|
WO/2023/283610A1 |
This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalen...
|
|
WO/2023/283425A1 |
Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2). The compou...
|
|
WO/2023/279773A1 |
Provided are a preparation method for a tedizolid intermediate represented by formula (I), and an intermediate. The method comprises: 1) reacting 2-fluoro-4-substituted phenylacetic acid with a Vilsmeier reagent, and then adding a reacti...
|
|
WO/2023/280254A1 |
Provided are a compound as shown in formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The definition of each group in formula (I) is as described in the present invent...
|
|
WO/2023/279211A1 |
The present disclosure relates to compounds of Formula I, element tags comprising soft metals, and methods and kits therefore for performing mass cytometry. Formula I
|
|
WO/2023/281271A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2023/279986A1 |
A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.
|
|
WO/2023/283606A1 |
Disclosed are bifunctional compounds and pharmaceutically acceptable salts and stereoisomers thereof that that are potent and selective degraders of LRRK2. Also disclosed are pharmaceutical compositions containing same, and methods of ma...
|
|
WO/2023/280296A1 |
Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.
|
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/280293A1 |
The present invention relates to a pyrrole sulfonyl derivative, a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, especially as a gastric acid secretion inhib...
|
|
WO/2023/283369A1 |
Provided herein are small molecule protein kinase modulators, pharmaceutical compositions comprising such, and their uses in treating one or more conditions.
|
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
|
WO/2023/278600A1 |
The disclosure relates to compounds that act as inhibitors of KRAS; pharmaceutical compositions comprising the compounds; and methods of treating or preventing disorders, including cancer and other proliferation diseases.
|
|
WO/2023/275337A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/274246A1 |
Provided are a compound as represented by formula (I), and a pharmaceutically acceptable salt, tautomer, mesomer, racemate, stereoisomer, metabolite, metabolic precursor or drug precursor thereof, an application thereof as a protein regu...
|
|
WO/2023/274397A1 |
Disclosed are a cyclin-dependent kinase 2 (CDK2) inhibitor as shown in formula I, a preparation method therefor and use thereof. The compound of formula I can be used as a CDK inhibitor for preventing and/or treating diseases associated ...
|
|
WO/2023/273384A1 |
Provided in the present disclosure are a thermally activated delayed fluorescent material, an organic light-emitting device and a display apparatus. The energy level difference between a singlet energy level and a triplet energy level of...
|
|
WO/2023/274251A1 |
The present invention relates to a polycyclic compound for inhibiting RNA helicase DHX33, and an application of the compound. In particular, the present invention relates to a compound as represented by formula I or a pharmaceutically ac...
|
|
WO/2023/277593A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/274040A1 |
Provided are a crystal form of a triazolopyridine-substituted indazole compound and a preparation method therefor; and specifically disclosed are a crystal form of a compound as represented by formula (I) and a preparation method therefor.
|
|
WO/2023/273997A1 |
An organic compound and an application thereof. The organic compound has a structure represented by formula I, has better stability and photoelectric properties, and can enhance and balance carrier transport, thereby improving device per...
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/278843A2 |
Provided herein are solid forms of osanetant, including salts thereof, processes for making the solid forms, and their therapeutic methods of use. Also provided is a process for preparing osanetant, and intermediates for use in the same.
|
|
WO/2023/275333A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2023/274390A1 |
Disclosed are a Bruton's tyrosine kinase and a mutant degrader thereof, or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug f...
|
|
WO/2023/275336A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/278564A1 |
The present invention relates to compounds that inhibit Protein Arginine N- Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods...
|
|
WO/2023/272720A1 |
PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor comp...
|
|
WO/2023/279105A1 |
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided ...
|
|
WO/2023/276813A1 |
The present invention addresses the problem of providing a pyridazinone compound which has excellent bactericidal/antibacterial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/horticu...
|
|
WO/2023/277446A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2023/277015A1 |
The present invention provides a compound having outstanding effectiveness against resistant harmful arthropods, a composition containing the same, and a control method. A compound represented by formula (I) [in which R1 denotes a C1-C6 ...
|
|
WO/2022/268520A1 |
The invention relates to the use of substituted pyrrolidinones of general formula (I), or their salts, wherein the groups in general formula (I) are defined as indicated in the description, for increasing the stress tolerance of plants w...
|
|
WO/2022/271801A1 |
The present disclosure provides methods of producing a compound of structural formula (I): (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/271846A1 |
Various salt and polymorph forms of Compound (I) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. Particular crystalline forms of 1:0.5 Compound (I) Semi-Succinate, 1:0....
|
